logoLANDING BIOTECH INC

Fax: 617-964-1187

EMAIL: sales@landingbiotech.com



HUMAN UROKINASE AMINO-TERMINAL FRAGMENT


Other Product Description
VEGF-165
Aprotinin
Urokinase
Prourokinase Non-glycosylated
Prourokinase Glycosylated
ATF
ATF II
Tissue Plasminogen
Activator

Glu-plasminogen
Lys-plasminogen
Plasmin
ETI

rEK

K2tPA

 

 

DESCRIPTION:
Amino-terminal fragment ( ATF, amino acid 1-135 ) was produced from pro-urokinase employing controlled Kellikrein cleavage, followed by autolysis. The structure of ATF consists of two individual modules: a growth factor domain (GFD) and a kringle domain. The N-terminal GFD is responsible for localizing urokinase and pro-urokinase on the cell surface by binding to the u-PA receptor (u-PAR), which promotes monocyte adhesion. Unlike homologous kringles of plasminogen and tissue plasmingen activator, the ATF kringle dose not bind to fibrin. Instead, the ATF kringle has been shown to bind heparin. ATF has no effect on plasminogen activation by urokinase, however, it is a competitive inhibitor for the binding of urokinase and pro-urokinase to u-PAR. N-terminal sequence analysis on ATF was performed with a PE/BD Procise 494 HT Protein Sequencing System. The molecular weight of ATF is about 15,000 dalton.

SOURCE:
Recombinant Pro-urokinase

PURITY:
Greater than 95% by SDS-PAGE.

ACTIVITY:
The adhesion of U937 monocyte to plastic surface was promoted by ATF. ATF binds unoccupied human u-PAR in a competitive manner, against pro-urokinase and urokinase.

PRESENTATION:
White lyophilized powder or solution.

STORAGE:
The lyophilized powder is best stored desiccated below 0 C. After it is reconstituted with sterile water or other buffered solutions, it should be stored at -20 C.


|Main Page |Top of the Page | Send us an Email |